Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
January 10, 2025 10:21 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting
January 07, 2025 09:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
July 18, 2024 09:00 ET
|
BIOXYTRAN, INC.
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
June 27, 2024 13:09 ET
|
BIOXYTRAN, INC.
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
February 21, 2024 08:00 ET
|
BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
Bioxytran Interview at the Emerging Growth Conference
October 04, 2023 09:00 ET
|
BIOXYTRAN, INC.
Thursday, October 5, 2023 10:15 am –10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage...
Bioxytran Interview at the Emerging Growth Conference
May 01, 2023 08:00 ET
|
BIOXYTRAN, INC.
Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)...
Bioxytran Interview at the Emerging Growth Conference
April 03, 2023 15:04 ET
|
BIOXYTRAN, INC.
Wednesday, April 5, 2023 10:50 am –11:20am ESTDiscussion of Peer Reviewed Article and Long COVID BOSTON, MASSACHUSETTS, April 03, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the...
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
February 28, 2023 08:00 ET
|
BIOXYTRAN, INC.
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
February 22, 2023 08:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat...